Natural innate cytokine response to immunomodulators and adjuvants in human precision-cut lung slices

Toxicology and Applied Pharmacology

Volumn 246, Issue 3, 2010, Pages 107-115

  Switalla, S ^a   Lauenstein, L ^a   Prenzler, F ^a   Knothe, S ^a   Forster C ^b   Fieguth, H G ^b   Pfennig, O ^b   Schaumann, F ^a   Martin, C ^c   Guzman, C A ^d   Ebensen, T ^d   Muller M ^a   Hohlfeld, J M ^a   Krug, N ^a   Braun, A ^a   Sewald, K ^a  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b Klinikum Region Hannover   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

BPPcysMPEG; Lipopolysaccharide; Organotypic culture; Precision cut lung slices; Proinflammatory cytokines

Indexed keywords

CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LUNG PARENCHYMA; LUNG SLICE; MALE; SIGNAL TRANSDUCTION; UPREGULATION;

ADULT; ANTI-INFLAMMATORY AGENTS; CHEMOKINE CCL4; CYTOKINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-1BETA; LIPOPEPTIDES; LIPOPOLYSACCHARIDES; LUNG; MALE; POLYETHYLENE GLYCOLS; TOLL-LIKE RECEPTORS;

BACTERIA (MICROORGANISMS);

EID: 77956870517     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.04.010     Document Type: Article

References (57)

1. Adcock I.M., Brown C.R., Kwon O., Barnes P.J. Oxidative stress induces NF kappa B DNA binding and inducible NOS mRNA in human epithelial cells. Biochem. Biophys. Res. Commun. 1994, 199:1518-1524.
2. Barnes P.J. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol. Allergy Clin. North Am. 2005, 25:451-468.
3. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Respir. J. 2003, 22:672-688.
4. Bihl F., Lariviere L., Qureshi S.T., Flaherty L., Malo D. LPS-hyporesponsiveness of mnd mice is associated with a mutation in Toll-like receptor 4. Genes Immun. 2001, 2:56-59.
5. Bless N.M., Huber-Lang M., Guo R.F., Warner R.L., Schmal H., Czermak B.J., Shanley T.P., Crouch L.D., Lentsch A.B., Sarma V., Mulligan M.S., Friedl H.P., Ward P.A. Role of CC chemokines (macrophage inflammatory protein-1 beta, monocyte chemoattractant protein-1, RANTES) in acute lung injury in rats. J. Immunol. 2000, 164:2650-2659.
6. Bosch V., Pfeiffer T., Devitt G., Allespach I., Ebensen T., Emerson V., Guzman C.A., Keppler O.T. HIV pseudovirion vaccine exposing Env "fusion intermediates"-response to immunisation in human CD4/CCR5-transgenic rats. Vaccine 2009, 27:2202-2212.
7. Bracke K.R., Demedts I.K., Joos G.F., Brusselle G.G. CC-chemokine receptors in chronic obstructive pulmonary disease. Inflamm. Allergy Drug Targets 2007, 6:75-79.
8. Carrega P., Morandi B., Costa R., Frumento G., Forte G., Altavilla G., Ratto G.B., Mingari M.C., Moretta L., Ferlazzo G. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 2008, 112:863-875.
9. Cazorla S.I., Frank F.M., Becker P.D., Corral R.S., Guzman C.A., Malchiodi E.L. Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model. Vaccine 2008, 26:1999-2009.
10. Deiters U., Barsig J., Tawil B., Muhlradt P.F. The macrophage-activating lipopeptide-2 accelerates wound healing in diabetic mice. Exp. Dermatol. 2004, 13:731-739.
11. Deiters U., Muhlradt P.F. Mycoplasmal lipopeptide MALP-2 induces the chemoattractant proteins macrophage inflammatory protein 1alpha (MIP-1alpha), monocyte chemoattractant protein 1, and MIP-2 and promotes leukocyte infiltration in mice. Infect. Immun. 1999, 67:3390-3398.
12. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
13. Doherty G.M., Lange J.R., Langstein H.N., Alexander H.R., Buresh C.M., Norton J.A. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J. Immunol. 1992, 149:1666-1670.
14. Doz E., Noulin N., Boichot E., Guenon I., Fick L., Le Bert M., Lagente V., Ryffel B., Schnyder B., Quesniaux V.F., Couillin I. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J. Immunol. 2008, 180:1169-1178.
15. Eder K., Vizler C., Kusz E., Karcagi I., Glavinas H., Balogh G.E., Vigh L., Duda E., Gyorfy Z. The role of lipopolysaccharide moieties in macrophage response to Escherichia coli. Biochem. Biophys. Res. Commun. 2009, 389:46-51.
16. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 1991, 147:3815-3822.
17. Fuchs B., Knothe S., Rochlitzer S., Nassimi M., Greweling M., Lauenstein H.D., Nassenstein C., Mueller M., Ebensen T., Dittrich A.M., Krug N., Guzman C.A., Braun A. A Toll-like receptor 2/6-agonist reduces allergic airway inflammation in chronic respiratory sensitisation to Timothy grass pollen antigens. Int. Arch. Allergy. Immunol. 2009, 152:131-139.
18. Hasday J.D., Bascom R., Costa J.J., Fitzgerald T., Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest 1999, 115:829-835.
19. Heinrich J., Pitz M., Bischof W., Krug N., Borm P.J.A. Endotoxin in fine (PM2.5) and coarse (PM2.5-10) particle mass of ambient aerosols: a temporo-spatial analysis. Atmos. Environ. 2003, 37:3659-3667.
20. Heinzel F.P., Rerko R.M., Ling P., Hakimi J., Schoenhaut D.S. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect. Immun. 1994, 62:4244-4249.
21. Hill A.T., Campbell E.J., Hill S.L., Bayley D.L., Stockley R.A. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am. J. Med. 2000, 109:288-295.
22. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004, 364:709-721.
23. Hogg J.C., Senior R.M. Chronic obstructive pulmonary disease - part 2: pathology and biochemistry of emphysema. Thorax 2002, 57:830-834.
24. Holt P.G., Strickland D.H., Wikstrom M.E., Jahnsen F.L. Regulation of immunological homeostasis in the respiratory tract. Nat. Rev. Immunol. 2008, 8:142-152.
25. Howard M., Muchamuel T., Andrade S., Menon S. Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med. 1993, 177:1205-1208.
26. Hunninghake G.W., Crystal R.G. Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. Am. Rev. Respir. Dis. 1983, 128:833-838.
27. Jorgens G., Bange F.C., Muhlradt P.F., Pabst R., Maus U.A., Tschernig T. Synthetic lipopeptide MALP-2 inhibits intracellular growth of Mycobacterium bovis BCG in alveolar macrophages-preliminary data. Inflammation 2009, 32:247-251.
28. Kaufmann A., Muhlradt P.F., Gemsa D., Sprenger H. Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2. Infect. Immun. 1999, 67:6303-6308.
29. Kerber-Momot T., Leemhuis D., Luhrmann A., Munder A., Tummler B., Pabst R., Tschernig T. Beneficial effects of TLR-2/6 ligation in pulmonary bacterial infection and immunization with Pseudomonas aeruginosa. Inflammation 2010, 33:58-64.
30. Kitz R., Rose M.A., Placzek K., Schulze J., Zielen S., Schubert R. LPS inhalation challenge: a new tool to characterize the inflammatory response in humans. Med. Microbiol. Immunol. 2008, 197:13-19.
31. Knorr C., Hubschle T., Murgott J., Muhlradt P., Gerstberger R., Roth J. Macrophage-activating lipopeptide-2 (MALP-2) induces a localized inflammatory response in rats resulting in activation of brain sites implicated in fever. Brain Res. 2008, 1205:36-46.
32. Kumar H., Kawai T., Akira S. Pathogen recognition in the innate immune response. Biochem. J. 2009, 420:1-16.
33. Macgregor J.T., Collins J.M., Sugiyama Y., Tyson C.A., Dean J., Smith L., Andersen M., Curren R.D., Houston J.B., Kadlubar F.F., Kedderis G.L., Krishnan K., Li A.P., Parchment R.E., Thummel K., Tomaszewski J.E., Ulrich R., Vickers A.E., Wrighton S.A. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol. Sci. 2001, 59:17-36.
34. Macnee W. Oxidative stress and lung inflammation in airways disease. Eur. J. Pharmacol. 2001, 429:195-207.
35. Martin M.D., Fingleton B., Lynch C.C., Wells S., Mcintyre J.O., Piston D.W., Matrisian L.M. Establishment and quantitative imaging of a 3D lung organotypic model of mammary tumor outgrowth. Clin. Exp. Metastasis 2008, 25:877-885.
36. Morr M., Takeuchi O., Akira S., Simon M.M., Muhlradt P.F. Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur. J. Immunol. 2002, 32:3337-3347.
37. Muhlradt P.F., Frisch M. Purification and partial biochemical characterization of a Mycoplasma fermentans-derived substance that activates macrophages to release nitric oxide, tumor necrosis factor, and interleukin-6. Infect. Immun. 1994, 62:3801-3807.
38. Muhlradt P.F., Schade U. MDHM, a macrophage-stimulatory product of Mycoplasma fermentans, leads to in vitro interleukin-1 (IL-1), IL-6, tumor necrosis factor, and prostaglandin production and is pyrogenic in rabbits. Infect. Immun. 1991, 59:3969-3974.
39. O'Grady N.P., Preas H.L., Pugin J., Fiuza C., Tropea M., Reda D., Banks S.M., Suffredini A.F. Local Inflammatory Responses following Bronchial Endotoxin Instillation in Humans. AJRCCM 2001, 163:1591-1598.
40. Olszewska-Pazdrak B., Casola A., Saito T., Alam R., Crowe S.E., Mei F., Ogra P.L., Garofalo R.P. Cell-specific expression of RANTES, MCP-1, and MIP-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J. Virol. 1998, 72:4756-4764.
41. Rajasingh J., Bord E., Luedemann C., Asai J., Hamada H., Thorne T., Qin G., Goukassian D., Zhu Y., Losordo D.W., Kishore R. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. FASEB J. 2006, 20:2112-2114.
42. Reppe K., Tschernig T., Luhrmann A., L.van V., Grote K., Zemlin M.V., Gutbier B., Muller H.C., Kursar M., Schutte H., Rosseau S., Pabst R., Suttorp N., Witzenrath M. Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia. Am. J. Respir. Cell Mol. Biol. 2009, 40:474-481.
43. Resnick J.S., Brown D.M., Vernier R.L. Oxygen toxicity in fetal organ culture. II. The developing lung. Lab. Invest. 1974, 31:665-677.
44. Ressmeyer A.R., Larsson A.K., Vollmer E., Dahlen S.E., Uhlig S., Martin C. Characterisation of guinea pig precision-cut lung slices: comparison with human tissues. Eur. Respir. J. 2006, 28:603-611.
45. Rharbaoui F., Drabner B., Borsutzky S., Winckler U., Morr M., Ensoli B., Muhlradt P.F., Guzman C.A. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur. J. Immunol. 2002, 32:2857-2865.
46. Rharbaoui F., Westendorf A., Link C., Felk S., Buer J., Gunzer M., Guzman C.A. The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect. Immun. 2004, 72:6978-6986.
47. Russell R.E., Thorley A., Culpitt S.V., Dodd S., Donnelly L.E., Demattos C., Fitzgerald M., Barnes P.J. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 283:L867-L873.
48. Schaumann F., Muller M., Braun A., Luettig B., Peden D.B., Hohlfeld J.M., Krug N. Endotoxin augments myeloid dendritic cell influx into the airways in patients with allergic asthma. Am. J. Respir. Crit. Care Med. 2008, 177:1307-1313.
49. Schulze K., Staib C., Schatzl H.M., Ebensen T., Erfle V., Guzman C.A. A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus. Vaccine 2008, 26:6678-6684.
50. Sha Q., Truong-Tran A.Q., Plitt J.R., Beck L.A., Schleimer R.P. Activation of airway epithelial cells by toll-like receptor agonists. Am. J. Respir. Cell Mol. Biol. 2004, 31:358-364.
51. Takeuchi O., Akira S. Toll-like receptors; their physiological role and signal transduction system. Int. Immunopharmacol. 2001, 1:625-635.
52. Takeuchi O., Kaufmann A., Grote K., Kawai T., Hoshino K., Morr M., Muhlradt P.F., Akira S. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. J. Immunol. 2000, 164:554-557.
53. van Eeden S.F., Sin D.D. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008, 75:224-238.
54. Weigt H., Muhlradt P.F., Emmendorffer A., Krug N., Braun A. Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells. Immunobiology 2003, 207:223-233.
55. Weigt H., Muhlradt P.F., Larbig M., Krug N., Braun A. The Toll-like receptor-2/6 agonist macrophage-activating lipopeptide-2 cooperates with IFN-gamma to reverse the Th2 skew in an in vitro allergy model. J. Immunol. 2004, 172:6080-6086.
56. Weigt H., Nassenstein C., Tschernig T., Muhlradt P.F., Krug N., Braun A. Efficacy of macrophage-activating lipopeptide-2 combined with interferon-gamma in a murine asthma model. Am. J. Respir. Crit. Care Med. 2005, 172:566-572.
57. Wohlsen A., Martin C., Vollmer E., Branscheid D., Magnussen H., Becker W.M., Lepp U., Uhlig S. The early allergic response in small airways of human precision-cut lung slices. Eur. Respir. J. 2003, 21:1024-1032.